Everett Harris & Co. CA Has $6.02 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Everett Harris & Co. CA reduced its position in Amgen Inc. (NASDAQ:AMGN) by 2.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 23,102 shares of the medical research company’s stock after selling 586 shares during the quarter. Everett Harris & Co. CA’s holdings in Amgen were worth $6,021,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of AMGN. Total Clarity Wealth Management Inc. boosted its stake in Amgen by 1.8% during the 4th quarter. Total Clarity Wealth Management Inc. now owns 9,018 shares of the medical research company’s stock valued at $2,350,000 after purchasing an additional 156 shares during the last quarter. Custom Index Systems LLC purchased a new position in Amgen during the fourth quarter worth about $274,000. Heck Capital Advisors LLC bought a new position in shares of Amgen during the 4th quarter worth approximately $36,000. Austin Private Wealth LLC grew its holdings in shares of Amgen by 19.9% in the fourth quarter. Austin Private Wealth LLC now owns 2,854 shares of the medical research company’s stock valued at $744,000 after acquiring an additional 473 shares in the last quarter. Finally, BTC Capital Management Inc. lifted its holdings in Amgen by 6.5% during the fourth quarter. BTC Capital Management Inc. now owns 6,190 shares of the medical research company’s stock worth $1,613,000 after acquiring an additional 378 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.5 %

Shares of Amgen stock opened at $285.42 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a 50-day moving average of $271.24 and a 200 day moving average of $304.84. The firm has a market cap of $153.42 billion, a price-to-earnings ratio of 36.55, a PEG ratio of 2.85 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.96 earnings per share. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.34%. The ex-dividend date is Friday, February 14th. Amgen’s payout ratio is presently 115.24%.

Wall Street Analyst Weigh In

Several analysts have commented on AMGN shares. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. Citigroup cut their price target on Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a report on Tuesday. Bank of America reiterated an “underperform” rating and set a $256.00 price objective on shares of Amgen in a research note on Tuesday, December 10th. Finally, Barclays lifted their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $314.00.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.